Please use this identifier to cite or link to this item:
http://hdl.handle.net/20.500.11889/8416
Title: | Availability and affordability of medicines and cardiovascular outcomes in 21 high-income, middle-income and low-income countries | Authors: | Chow, Clara Kayei Nguyen, Tu Ngoc Marschner, Simone Diaz, Rafael Rahman, Omar Avezum, Alvaro Lear, Scott A. Teo, Koon Yeates, Karen E. Lanas, Fernando Li, Wei Hu, Bo Lopez-Jaramillo, Patricio Gupta, Rajeev Kumar, Rajesh Mony, Prem K. Bahonar, Ahmad Yusoff, Khalid Khatib, Rasha Kazmi, Khawar Dans, Antonio L. Zatonska, Katarzyna Alhabib, Khalid F. Kruger, Iolanthe Marike Rosengren, Annika Gulec, Sadi Yusufali, Afzalhussein Chifamba, Jephat Rangarajan, Sumathy McKee, Martin Yusuf, Salim |
Keywords: | Drug therapy - Standards;Cardiovascular diseases - Prevention and control;Health services accessibility;Medical anthropology;Drug accessibility, Cardiovascular | Issue Date: | 2020 | Publisher: | BMJ Global Health | Abstract: | Objectives We aimed to examine the relationship between access to medicine for cardiovascular disease (CVD) and major adverse cardiovascular events (MACEs) among people at high risk of CVD in high-income countries (HICs), upper and lower middle-income countries (UMICs, LMICs) and low-income countries (LICs) participating in the Prospective Urban Rural Epidemiology (PURE) study. Methods We defined high CVD risk as the presence of any of the following: hypertension, coronary artery disease, stroke, smoker, diabetes or age >55 years. Availability and affordability of blood pressure lowering drugs, antiplatelets and statins were obtained from pharmacies. Participants were categorised: group 1—all three drug types were available and affordable, group 2—all three drugs were available but not affordable and group 3—all three drugs were not available. We used multivariable Cox proportional hazard models with nested clustering at country and community levels, adjusting for comorbidities, sociodemographic and economic factors. Results Of 163 466 participants, there were 93 200 with high CVD risk from 21 countries (mean age 54.7, 49% female). Of these, 44.9% were from group 1, 29.4% from group 2 and 25.7% from group 3. Compared with participants from group 1, the risk of MACEs was higher among participants in group 2 (HR 1.19, 95% CI 1.07 to 1.31), and among participants from group 3 (HR 1.25, 95% CI 1.08 to 1.50). Conclusion Lower availability and affordability of essential CVD medicines were associated with higher risk of MACEs and mortality. Improving access to CVD medicines should be a key part of the strategy to lower CVD globally. | URI: | http://hdl.handle.net/20.500.11889/8416 | DOI: | 10.1136/bmjgh-2020-002640 |
Appears in Collections: | Fulltext Publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Availability and affordability of medicines and cardiovascular outcomes in 21 high-income, middle-income and low-income countries.pdf | 2.46 MB | Adobe PDF | View/Open |
Page view(s)
9
checked on Jan 20, 2024
Download(s)
2
checked on Jan 20, 2024
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.